Please assess the completion status of the following clinical trial:

Trial Title: Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who understand and sign the consent form for this study.~* Age: 40-70, males and females.~* Clinical diagnosis of degenerative arthritis by Radiographic Criteria of Kellgren and Lawrence.~* Patients who can't treat with traditional medication and need a arthroplasty.~* Duration of pain over Grade 4(11-point numeric scale)\> 4 months.~Exclusion Criteria:~* Women who are pregnant or breast feeding or planning to become pregnant during the study.~* Objects who administer with a anti-inflammatory drugs within 14 days prior to inclusion in the study.~* History or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications.~* Treatment with intra-articular injection therapy within 2 months prior to screen.~* Other joint diseases except degenerative arthritis : systemic or rheumatic or inflammatory chondropathy, chondrocalcinosis, hemachromatosis, inflammatory joint disease, avascular necrosis of the femoral head, Paget's disease, hemophilic arthropathy, infectional arthritis, Charcot's disease, villonodular synovitis, synovial chondromatosis.~* Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C (Anti-HCV-Ab) and syphilis.~* Serious pre-existing medical conditions like Cardiovascular Diseases, Renal Diseases, Liver Diseases, Endocrine Diseases, Cancer and Diabetes Mellitus.~* Overweight expressed as body mass index (BMI) greater than 30 (obesity grade II).~* Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cells low-dose group (Type: EXPERIMENTAL): Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
- Mesenchymal stem cells mid-dose group (Type: EXPERIMENTAL): Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
- Mesenchymal stem cells high-dose group (Type: EXPERIMENTAL): Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).